Black Lung Disease Market: Global Industry Analysis and Forecast (2024-2030)

  • The Black Lung Disease Market size was valued at USD 15.65 Bn. in 2023 and the total Global Black Lung Disease revenue is expected to grow at a CAGR of 13.99% from 2024 to 2030, reaching nearly USD 39.16 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2053

Black Lung Disease Market Overview

Underground mining is one of the most dangerous occupations in the world. Risks include inhaling toxic gases, such as methane, carbon monoxide and hydrogen sulfide, being crushed by roof falls or mining equipment, drowning when tunnels fill with water, and injury in fires and explosions. Even if miners survive the workplace, they suffocate to death years later. The black lung disease market is witnessing significant growth driven by the increasing prevalence of coal workers' pneumoconiosis (CWP) and related respiratory conditions among coal miners globally. This occupational lung disease, caused by prolonged exposure to coal dust containing hazardous particles like silica, leads to inflammation, fibrosis, and potentially severe lung damage over time.

 

The key factors shaping the black lung disease market include Prevalence and Incidence, Technological Advancements, and Regulatory Landscape. The market is characterized by increasing research and development activities focused on developing new therapies and improving existing treatments for black lung disease. Strategic collaborations between pharmaceutical companies and research institutions are key drivers in advancing treatment options. Despite advancements, challenges such as limited awareness about preventive measures, high treatment costs, and the irreversible nature of lung damage in advanced stages of the disease remain significant barriers to market growth.

 

  • Stellar analysis projected that coal is used to produce approximately 40% of the electricity worldwide and 34% in the United States until 2040.

Black Lung Disease Market

 

To get more Insights: Request Free Sample Report

 

Black Lung Disease Market Dynamics

Silica Exposure Drives Surge in Black Lung Disease Market

The rising rates of coal workers’ pneumoconiosis, commonly known as black lung disease, are significantly driven by silica exposure, as highlighted by recent research from the University of Illinois Chicago and its collaborators. This groundbreaking study is the first to compare the pathology and mineralogy of black lung disease across generations, providing scientific evidence for the increasing prevalence of progressive massive fibrosis (PMF) among younger coal workers in regions such as West Virginia, Virginia, and Kentucky.

 

A $750,000 grant from the Alpha Foundation for the Improvement of Mining Safety and Health supports ongoing research at the University of Illinois at Chicago (UIC) Mining Education and Research Center. This research aims to elucidate how various mining dusts contribute to lung disease. The center, part of the UIC School of Public Health, manages several projects, including a $1.8 million grant focused on understanding the rise in mine dust-related lung diseases such as progressive massive fibrosis and rapidly progressive pneumoconiosis.

Black Lung Disease Market1

Increased Demand for Advanced Diagnostic and Treatment Solutions

A significant trend in the black lung disease market is the growing demand for advanced diagnostic and treatment solutions. This trend is driven by the rising incidence of coal workers’ pneumoconiosis (CWP), also known as black lung disease, particularly the severe forms such as progressive massive fibrosis (PMF). As the disease becomes more prevalent, especially among younger miners, there is an urgent need for more effective medical interventions and technologies.

 

  • Advanced Diagnostic Tools: The increasing complexity and severity of black lung disease cases have necessitated the development of advanced diagnostic tools. Imaging technologies such as high-resolution CT scans and advanced pulmonary function tests are becoming standard in identifying and monitoring the progression of the disease. These tools enable early detection and more accurate assessment of lung damage, leading to better management of the condition.
  • Innovative Treatment Approaches: There is also a noticeable shift towards innovative treatment approaches. Traditional treatments like bronchodilators and oxygen therapy remain essential, but emerging therapies such as stem cell treatments and personalized medicine are gaining traction. These advanced therapies aim to not only alleviate symptoms but also repair lung tissue and improve overall lung function.
  • Enhanced Regulatory Measures: There is a growing emphasis on enhancing regulatory measures to protect coal miners. New findings linking silica exposure to severe forms of black lung disease have prompted calls for stricter regulations on permissible dust exposure levels. Regulatory bodies are considering updating standards to reduce the allowable concentration of respirable dust in mining environments, thereby mitigating the risk of disease.
  • Improved Healthcare Infrastructure: The market is also witnessing improvements in healthcare infrastructure, particularly in regions heavily affected by black lung disease. Specialized clinics and healthcare centres focusing on occupational lung diseases are being established, offering comprehensive care that includes diagnostic, therapeutic, and rehabilitative services. These centres play a crucial role in managing the disease and improving the quality of life for affected miners.

 

Black Lung Disease Market Segment Analysis

Based on Diagnosis, the imaging (including X-rays and CT scans) segment held the largest Black Lung Disease Market share of about 35% in 2023. According to the Stellar analysis, the segment is expected to grow at a CAGR of 14.1 % during the forecast period (2024- 2030) and maintain its dominance till 2030. Imaging is the primary diagnostic tool due to its non-invasive nature, widespread availability, and ability to provide clear evidence of lung abnormalities consistent with black lung disease. Regular chest X-rays are a standard part of the screening process for workers in industries with high dust exposure. The adoption of high-resolution CT scans further enhances diagnostic accuracy, making imaging the preferred method for early detection and ongoing monitoring.

 

  • Estimates around 16% of coal miners in the United States eventually have lung issues from coal dust.

Black Lung Disease Market2

Pulmonary function tests (PFTs) segment held the second largest market share of about 25% in 2023. The pulmonary function tests (PFTs) are essential for evaluating the impact of black lung disease on lung capacity and function. These tests are non-invasive and provide valuable information about the progression of the disease and the patient's ability to breathe. They are crucial for both diagnosis and monitoring the disease's progression.

 

Biopsy, while critical for confirming black lung disease, is less frequently used as a first-line diagnostic tool due to its invasive nature. It is typically reserved for cases where other diagnostic methods are inconclusive.

 

Black Lung Disease Market Regional Analysis

North America has dominated the Black Lung Disease Market, which held the largest market share accounting for 47.10% in 2023, the region is expected to grow during the forecast period and maintain its dominance by 2030. Black lung disease, known as coal worker’s pneumoconiosis (CWP), affects a significant proportion of coal miners in North America, primarily in the United States where coal mining remains prominent.

 

  • The estimates indicate that approximately 16% of coal workers in the U.S. are affected by CWP, marking a concerning resurgence in the disease despite decades of regulatory efforts.
  • Government agencies like the Occupational Safety and Health Administration (OSHA) play a crucial role in regulating workplace safety standards to mitigate CWP risks.

Black Lung Disease Market3

The prevalence of CWP varies across different regions within North America, influenced by factors such as mining intensity, geological characteristics of coal deposits, and adherence to safety regulations. States with historically intensive coal mining operations, such as West Virginia, Kentucky, and Pennsylvania, report higher incidences of CWP compared to regions with less concentrated mining activities. The market for CWP treatment and management in North America is growing in response to increasing disease prevalence.

 

Medical services catering to occupational lung diseases, including diagnostic imaging, pulmonary function testing, and specialized rehabilitation programs, are expanding to meet the rising demand. Healthcare facilities in major mining regions are focusing on developing comprehensive care plans that address both the medical and occupational aspects of CWP. In terms of market dynamics, there is a growing need for innovative therapies and medical devices that can improve the quality of life for CWP patients. Research and development efforts are focusing on better understanding the disease mechanisms and developing targeted treatments to alleviate symptoms and slow disease progression.

 

Black Lung Disease Market Competitive Landscape

  1. In May 2024, Pfizer announced on Friday that its drug Lorbrena showed promising long-term results in treating advanced lung cancer in a late-stage trial. The study revealed that Lorbrena significantly extended patients' lives without cancer progression, with many experiencing benefits for over five years, and reduced the risk of brain metastases by 94%. Pfizer's new data, presented at the ASCO annual meeting, suggests Lorbrena become the new standard first-line treatment for ALK-positive non-small cell lung cancer.
  2. In march 2024, Merck's new drug, Winrevair, received FDA approval as the first in its class for treating pulmonary arterial hypertension (PAH), targeting a key signaling pathway of the disease. The approval follows Merck's $11.5 billion acquisition of Acceleron Pharma and is based on promising Phase 3 trial results showing significant improvement in exercise capacity and a reduction in mortality risk for PAH patients.
  3. In February 2024, AstraZeneca announced on Monday that its leading drug, Tagrisso, significantly slowed the progression of early-stage non-small cell lung cancer in patients with an epidermal growth factor receptor mutation. The trial results showed a "statistically significant and highly clinically meaningful" improvement, leading to a 3% rise in shares. The company aims to present further survival data later this year.

                                                             Black Lung Disease Market Scope

Market Size in 2023

USD 15.65 Bn.

Market Size in 2030

USD 39.16 Bn.

CAGR (2024-2030)

13.99 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

Segments

By Treatment

Oxygen Therapy

Lung Transplant

Stem cell Therapy

Bronchodilator

Others

By Type

Simple

Complicated

By Diagnosis

Biospy

Imaging

Full Blood Count

Pulmonary/Lung Function Tests

Physical Examination

Others

By End Users

Hospitals And Clinics

Research Organizations and Academic Institutes

Diagnostic Centers and labs

Regional Scope

North America (United States), Canada, and Mexico

Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Key Player in the Black Lung Disease Market

  1. Pfizer Inc
  2. Boehringer Ingelheim International GmbH
  3. GlaxoSmithKline plc
  4. Novartis AG
  5. Teva Pharmaceutical Industries Ltd.
  6. AstraZeneca
  7. Koninklijke Philips N.V.
  8. GENERAL ELECTRIC
  9. Siemens AG
  10. Medtronic PLC
  11. F. Hoffmann-La Roche AG
  12. Merck and Co.Inc
  13. Bayer AG
  14. Sanofi S.A
  15. Melinta Therapeutics LLC
  16. Eli Lilly and Company
  17. Mayo Clinics
  18. Baxter International Inc
  19. Sun Pharmaceutical Industries Ltd
  20. Perrigo Lab India Pvt Ltd
  21. Aurobindo Pharma Limited
  22. Hikma Pharmaceutical PLC
  23. Lupin Limited


Frequently Asked Questions

The Black Lung Disease Market is expected to grow at a CAGR of 13.99 % during the forecast period of 2023 to 2030.

1.    Black Lung Disease Market: Research Methodology 
2.    Black Lung Disease Market: Executive Summary
3.    Black Lung Disease Market: Competitive Landscape

3.1. Stellar Competition Matrix
3.2. Competitive Landscape
3.3. Key Players Benchmarking
3.4. Market Structure
3.4.1.    Market Leaders 
3.4.2.    Market Followers
3.4.3.    Emerging Players

3.5. Consolidation of the Market
3.6. Global Import-Export Analysis
4.    Black Lung Disease Market: Dynamics
4.1. Market Driver 
4.2. Market Trends 
4.3. Market Restraints
4.4. Market Opportunities
4.5. Market Challenges
4.6. PORTER’s Five Forces Analysis
4.7. PESTLE Analysis
4.8. Strategies for New Entrants to Penetrate the Market
4.9. Regulatory Landscape by Region
4.9.1.    North America
4.9.2.    Europe
4.9.3.    Asia Pacific
4.9.4.    Middle East and Africa
4.9.5.    South America

5.    Black Lung Disease Market Size and Forecast by Segments (by Value in USD Billion)
5.1. Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
5.1.1.    Oxygen Therapy
5.1.2.    Lung Transplant
5.1.3.    Stem cell Therapy
5.1.4.    Bronchodilator
5.1.5.    Others

5.2. Black Lung Disease Market Size and Forecast, by Type (2023-2030)
5.2.1.    Simple
5.2.2.    Complicated

5.3. Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
5.3.1.    Biospy
5.3.2.    Imaging
5.3.3.    Full Blood Count
5.3.4.    Pulmonary/Lung Function Tests
5.3.5.    Physical Examination
5.3.6.    Others

5.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
5.4.1.    Hospitals And Diagnostic Centers and labs
5.4.2.    Research Organizations and Academic Institutes
5.4.3.    Diagnostic Centers and labs

5.5. Black Lung Disease Market Size and Forecast, by Region (2023-2030)
5.5.1.    North America
5.5.2.    Europe
5.5.3.    Asia Pacific
5.5.4.    Middle East and Africa
5.5.5.    South America

6.    North America Black Lung Disease Market Size and Forecast (by Value in USD Billion )
6.1. North America Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
6.1.1.    Oxygen Therapy
6.1.2.    Lung Transplant
6.1.3.    Stem cell Therapy
6.1.4.    Bronchodilator
6.1.5.    Others

6.2.  North America Black Lung Disease Market Size and Forecast, by Type (2023-2030)
6.2.1.    Simple
6.2.2.    Complicated

6.3. North America Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
6.3.1.    Biospy
6.3.2.    Imaging
6.3.3.    Full Blood Count
6.3.4.    Pulmonary/Lung Function Tests
6.3.5.    Physical Examination
6.3.6.    Others

6.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
6.4.1.    Hospitals And Diagnostic Centers and labs
6.4.2.    Research Organizations and Academic Institutes
6.4.3.    Diagnostic Centers and labs

6.5. North America Black Lung Disease Market Size and Forecast, by Country (2023-2030)
6.5.1.    United States
6.5.2.    Canada
6.5.3.    Mexico

7.    Europe Black Lung Disease Market Size and Forecast (by Value in USD Billion )
7.1. Europe Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
7.1.1.    Oxygen Therapy
7.1.2.    Lung Transplant
7.1.3.    Stem cell Therapy
7.1.4.    Bronchodilator
7.1.5.    Others

7.2.  Europe Black Lung Disease Market Size and Forecast, by Type (2023-2030)
7.2.1.    Simple
7.2.2.    Complicated

7.3. Europe Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
7.3.1.    Biospy
7.3.2.    Imaging
7.3.3.    Full Blood Count
7.3.4.    Pulmonary/Lung Function Tests
7.3.5.    Physical Examination
7.3.6.    Others

7.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
7.4.1.    Hospitals And Diagnostic Centers and labs
7.4.2.    Research Organizations and Academic Institutes
7.4.3.    Diagnostic Centers and labs

7.5. Europe Black Lung Disease Market Size and Forecast, by Country (2023-2030)
7.5.1.    UK
7.5.2.    France
7.5.3.    Germany
7.5.4.    Italy
7.5.5.    Spain
7.5.6.    Sweden
7.5.7.    Austria
7.5.8.    Rest of Europe

8.    Asia Pacific Black Lung Disease Market Size and Forecast (by Value in USD Billion )
8.1. Asia Pacific Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
8.1.1.    Oxygen Therapy
8.1.2.    Lung Transplant
8.1.3.    Stem cell Therapy
8.1.4.    Bronchodilator
8.1.5.    Others

8.2.  Asia Pacific Black Lung Disease Market Size and Forecast, by Type (2023-2030)
8.2.1.    Simple
8.2.2.    Complicated

8.3. Asia Pacific Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
8.3.1.    Biospy
8.3.2.    Imaging
8.3.3.    Full Blood Count
8.3.4.    Pulmonary/Lung Function Tests
8.3.5.    Physical Examination
8.3.6.    Others

8.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
8.4.1.    Hospitals And Diagnostic Centers and labs
8.4.2.    Research Organizations and Academic Institutes
8.4.3.    Diagnostic Centers and labs

8.5. Asia Pacific Black Lung Disease Market Size and Forecast, by Country (2023-2030)
8.5.1.    China
8.5.2.    S Korea
8.5.3.    Japan
8.5.4.    India
8.5.5.    Australia
8.5.6.    Indonesia 
8.5.7.    Malaysia
8.5.8.    Vietnam
8.5.9.    Taiwan
8.5.10.    Bangladesh 
8.5.11.    Pakistan
8.5.12.    Rest of Asia Pacific

9.    Middle East and Africa Black Lung Disease Market Size and Forecast (by Value in USD Billion)
9.1. Middle East and Africa Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
9.1.1.    Oxygen Therapy
9.1.2.    Lung Transplant
9.1.3.    Stem cell Therapy
9.1.4.    Bronchodilator
9.1.5.    Others

9.2.  Middle East and Africa Black Lung Disease Market Size and Forecast, by Type (2023-2030)
9.2.1.    Simple
9.2.2.    Complicated

9.3. Middle East and Africa Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
9.3.1.    Biospy
9.3.2.    Imaging
9.3.3.    Full Blood Count
9.3.4.    Pulmonary/Lung Function Tests
9.3.5.    Physical Examination
9.3.6.    Others

9.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
9.4.1.    Hospitals And Diagnostic Centers and labs
9.4.2.    Research Organizations and Academic Institutes
9.4.3.    Diagnostic Centers and labs

9.5. Middle East and Africa Single-Use Filtration Assembly Market Size and Forecast, by Country (2023-2030)
9.5.1.    South Africa
9.5.2.    GCC
9.5.3.    Egypt
9.5.4.    Nigeria
9.5.5.    Rest of ME&A

10.    South America Black Lung Disease Market Size and Forecast (by Value in USD Billion)
10.1. South America Black Lung Disease Market Size and Forecast, by Treatment (2023-2030)
10.1.1.    Oxygen Therapy
10.1.2.    Lung Transplant
10.1.3.    Stem cell Therapy
10.1.4.    Bronchodilator
10.1.5.    Others

10.2.  South America Black Lung Disease Market Size and Forecast, by Type (2023-2030)
10.2.1.    Simple
10.2.2.    Complicated

10.3. South America Black Lung Disease Market Size and Forecast, by Diagnosis (2023-2030)
10.3.1.    Biospy
10.3.2.    Imaging
10.3.3.    Full Blood Count
10.3.4.    Pulmonary/Lung Function Tests
10.3.5.    Physical Examination
10.3.6.    Others

10.4. Black Lung Disease Market Size and Forecast, by End Users (2023-2030)
10.4.1.    Hospitals And Diagnostic Centers and labs
10.4.2.    Research Organizations and Academic Institutes
10.4.3.    Diagnostic Centers and labs

10.5. South America Black Lung Disease Market Size and Forecast, by Country (2023-2030)
10.5.1.    Brazil
10.5.2.    Argentina
10.5.3.    Rest of South America

11.    Company Profile: Key players
11.1. Pfizer Inc
11.1.1.    Company Overview
11.1.2.    Financial Overview
11.1.3.    Business Portfolio
11.1.4.    SWOT Analysis
11.1.5.    Business Strategy 
11.1.6.    Recent Developments

11.2. Boehringer Ingelheim International GmbH (Germany)
11.3. GlaxoSmithKline plc 
11.4. Novartis AG 
11.5. Teva Pharmaceutical Industries Ltd. 
11.6. AstraZeneca 
11.7. Koninklijke Philips N.V. 
11.8. GENERAL ELECTRIC 
11.9. Siemens AG 
11.10. Medtronic PLC 
11.11. F. Hoffmann-La Roche AG
11.12. Merck and Co.Inc
11.13. Bayer AG
11.14. Sanofi S.A
11.15. Melinta Therapeutics LLC
11.16. Eli Lilly and Company
11.17. Mayo Clinics
11.18. Baxter International Inc
11.19. Sun Pharmaceutical Industries Ltd
11.20. Perrigo Lab India Pvt Ltd
11.21. Aurobindo Pharma Limited
11.22. Hikma Pharmaceutical PLC
11.23. Lupin Limited
12.    Key Findings
13.    Industry Recommendations 

Enquiry Before Buy


Request Sample PDF